In a 49‑year‑old man with bladder pain, urinary frequency, occasional sildenafil use, PSA 1.17 ng/mL, and a urine dipstick showing a small amount of blood and trace leukocytes, what are the appropriate next diagnostic and therapeutic steps?

Diagnostic and Therapeutic Approach to Bladder Pain with Microscopic Hematuria

Confirm the microscopic hematuria with formal microscopic urinalysis showing ≥3 RBCs per high-powered field, then pursue concurrent evaluation for both interstitial cystitis/bladder pain syndrome (IC/BPS) and urologic malignancy given this patient's age, symptoms, and hematuria. 1

Immediate Next Steps

Confirm the Hematuria

• Obtain microscopic urinalysis to confirm ≥3 erythrocytes per high-powered field before proceeding with extensive workup. The dipstick showing "small blood" requires microscopic confirmation, as dipstick alone is insufficient for clinical decision-making. 1
• Send urine culture even with minimal leukocytes on dipstick, as clinically significant bacteriuria can exist below dipstick detection thresholds and must be excluded before diagnosing IC/BPS. 2

Rule Out Infection and Malignancy

• Do not obtain urinary cytology or urine-based molecular markers at this initial stage—they are not recommended for initial hematuria evaluation. 1
• Document that symptoms have been present for at least 6 weeks with negative urine cultures to meet IC/BPS diagnostic criteria. 2

Urologic Referral Decision

Refer to urology for cystoscopy and imaging given the confirmed microscopic hematuria in a 49-year-old man, even though he lacks gross hematuria. 1 This recommendation stands because:

• The American College of Physicians advises urology referral for microscopically confirmed hematuria in the absence of demonstrable benign cause. 1
• Bladder cancer must be excluded in this age group with bladder pain and hematuria, particularly given any tobacco exposure history. 2
• The AUA guidelines specifically note that bladder cancer, stones, and foreign bodies are clinical mimics of IC/BPS requiring cystoscopic exclusion. 2

Cystoscopy Serves Dual Purpose

The cystoscopy will simultaneously:

1. Exclude malignancy, stones, and foreign bodies that could explain symptoms 2
2. Identify Hunner lesions if present, which would direct IC/BPS treatment toward early fulguration/resection rather than requiring failed conservative therapies first 2

Baseline Symptom Documentation

Before initiating any IC/BPS treatment, establish:

• Voiding diary (minimum 1 day) documenting frequency, voided volumes, and pain patterns. Very low frequencies or high volumes should prompt alternative diagnoses. 2
• Pain assessment using validated tools (GUPI, ICSI, or VAS) 2
• Document dysuria, constant urge sensation, pain character/location/severity, and relationship to sexual activity 2
• Perform brief neurological exam and assess for incomplete bladder emptying to exclude neurologic causes or retention 2

Treatment Considerations

Sildenafil Is Not Contributory

The occasional sildenafil use is not causing these symptoms. While sildenafil has been studied for LUTS/BPH and even IC/BPS, the FDA labeling does not list bladder pain or hematuria as adverse effects. 3, 4, 5 This is a red herring in the clinical picture.

Initial IC/BPS Management (After Malignancy Excluded)

If cystoscopy and imaging exclude malignancy:

• Begin multimodal conservative therapy unless Hunner lesions are found 2
• If Hunner lesions are identified, proceed directly to lesion treatment (fulguration/resection) without requiring failed conservative therapies 2
• Periodically reassess treatment efficacy and discontinue ineffective interventions 2

Critical Pitfalls to Avoid

• Do not dismiss hematuria even with concurrent bladder pain symptoms—malignancy evaluation takes priority over IC/BPS diagnosis 2, 1
• Do not skip microscopic confirmation of dipstick hematuria before initiating extensive workup 1
• Do not delay urology referral waiting for symptom resolution or empiric treatment trials in a middle-aged man with hematuria 1
• Do not attribute symptoms to sildenafil use and miss underlying pathology 3
• The normal PSA (1.17 ng/mL) does not exclude bladder pathology and should not provide false reassurance 2